Showing 241 - 260 results of 463 for search '"Atrial fibrillation"', query time: 0.08s Refine Results
  1. 241

    Clinical Usefulness of Atrioventricular Coupling in Cardiovascular Disease by Yang Lan, Li Zhenyi, Chen Ya, Chen Anni, Wang Xinqi, Jin Lin, Li Zhaojun

    Published 2025-03-01
    Subjects: “…|echocardiography|atrioventricular coupling|left atrioventricular coupling index|heart failure|atrial fibrillation…”
    Get full text
    Article
  2. 242
  3. 243
  4. 244
  5. 245

    Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge‐to‐Edge Repair in Patients With Atrial Fibrillation: A Single‐Center Observational Study by Jan‐Hendrik Schipper, Anne‐Sophie Sommer, Richard Julius Nies, Clemens Metze, Max Maria Meertens, Jonas Wörmann, Sebastian Dittrich, Jan‐Hendrik van den Bruck, Arian Sultan, Jakob Lüker, Daniel Steven, Christopher Hohmann, Roman Pfister, Stephan Baldus, Ingo Eitel, Christian Frerker, Tobias Schmidt

    Published 2025-02-01
    “…Background Mitral valve transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a viable therapy option in patients with severe mitral regurgitation and high surgical risk. Although atrial fibrillation is common among patients undergoing M‐TEER, the optimal anticoagulatory treatment after the intervention is unknown. …”
    Get full text
    Article
  6. 246
  7. 247

    Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry by Ralf E Harskamp, Karen Pieper, A John Camm, Ajay K Kakkar, Jelle C L Himmelreich, Saverio Virdone, Jean-Pierre Bassand, Frank Misselwitz, Freek W A Verheugt, Frank Cools, Harry Gibbs, Antônio C Pereira-Barretto

    Published 2025-01-01
    “…Aims This study aimed to determine the robustness, reproducibility and representativeness of the landmark Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (AF) (ARISTOTLE) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in AF (ROCKET AF) randomised trials through replication in an observational AF patient registry.Methods and results Patients from the Global Anticoagulant Registry in the FIELD (GARFIELD)-AF registry treated with apixaban, rivaroxaban or vitamin K antagonist (VKA) were assessed for eligibility for the ARISTOTLE and ROCKET AF trials. …”
    Get full text
    Article
  8. 248

    Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care by Luis Alberto García Rodríguez, Pareen Vora, Luke Roberts, Gunnar Brobert, Samuel Fatoba, María Eugenia Sáez, Antonio González-Pérez

    Published 2022-06-01
    “…Objectives To investigate effects of appropriately and inappropriately dosed apixaban/rivaroxaban versus warfarin on effectiveness and safety outcomes in patients with non-valvular atrial fibrillation (NVAF).Design Cohort study with nested case–control analyses using primary care electronic health records (IQVIA Medical Research Data UK database).Setting UK primary care.Participants Patients aged ≥18 years with NVAF newly prescribed apixaban (N=14 701), rivaroxaban (N=14 288) or warfarin (N=16 175) between 1 January 2012 and 30 June 2018, and followed up to 31 December 2018.Primary and secondary outcome measures Incident cases of ischaemic stroke/systemic embolism (IS/SE) and intracranial bleeding (ICB). …”
    Get full text
    Article
  9. 249

    Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database by Gregory Y H Lip, Sally Lee, Brigitta U Monz, Andreas Clemens, Martina Brueckmann

    Published 2012-12-01
    “…Objective Three oral anticoagulants have reported study results for stroke prevention in patients with atrial fibrillation (AF) (dabigatran etexilate, rivaroxaban and apixaban); all demonstrated superiority or non-inferiority compared with warfarin (RE-LY, ARISTOTLE and ROCKET-AF). …”
    Get full text
    Article
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255

    Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding: A cohort study based on the French National Health Data System (SNDS). by Gregory Y H Lip, Robert Benamouzig, Anne-Céline Martin, Giancarlo Pesce, Gaelle Gusto, Nadia Quignot, Artak Khachatryan, Feng Dai, Fouad Sedjelmaci, Jose Chaves, Rupesh Subash, Ruth Mokgokong

    Published 2025-01-01
    “…<h4>Background</h4>Risk factors and comorbidities can complicate management of non-valvular atrial fibrillation. We describe and compare real-world safety and effectiveness of direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) and vitamin K antagonists (VKAs) in subgroups of patients with non-valvular atrial fibrillation at high risk for gastrointestinal (GI) bleeding, utilizing data from a national quasi-exhaustive French database.…”
    Get full text
    Article
  16. 256
  17. 257
  18. 258
  19. 259
  20. 260